Current available jobs worldwide.
Join our team
News and Features
9-23-2016: U.S. FDA Approves Labeling Update of Rexulti® (brexpiprazole) For Maintenance Treatment of Schizophrenia
7-7-2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
6-23-2016: U.S. FDA Approves Changes to the SABRIL® (vigabatrin) REMS Program
Progress in Mind
Lundbeck is dedicated to raising awareness and research into psychiatric and neurological disorders.Learn more on our corporate website